Advertisement

ERG Gene Variations and Risk of ALL in Hispanic Children

Advertisement

Key Points

  • The investigators identified high-risk variations in ERG that were associated with a 1.56-fold increased risk of ALL in Hispanic children.
  • The risk was highest (doubled) for children with the highest percentage of Native American ancestry and lowest (13%) for children with the lowest percentage.
  • In contrast, investigators found no significant increase in ALL risk among African American children with the high-risk ERG variations, and just a 12% elevated risk in children of European ancestry.

Scientists have identified genetic variations in a fourth gene that are associated with an increased risk of acute lymphoblastic leukemia (ALL) in Hispanic children. These findings were published by Qian et al in Blood.

The gene is ERG, a transcription factor that is also mutated in the leukemic cells of some patients with ALL. In this study, researchers identified inherited genetic variations in ERG that contribute to ALL risk, primarily in Hispanic children. These are germline variants carried in cells throughout the body, rather than the previously reported somatic mutations in cancer cells.

ALL is the most common childhood cancer, and Hispanic children have the nation’s highest incidence of the disease. They are also less likely than other children with ALL to survive.

“The more we understand the biology behind these disparities, the more likely we are to develop more effective therapies for different patient populations or better methods to track and monitor disease risk,” said corresponding study author Jun J. Yang, PhD, an associate member of the Hematological Malignancies Program of the St. Jude Comprehensive Cancer Center and in the Pharmaceutical Sciences Department, in a statement.

Study Methods

The study was a collaboration with the Children’s Oncology Group and one of the largest efforts yet focused on Hispanic patients with ALL. Dr. Yang and colleagues compared common genetic variations in 940 patients genetically defined as Hispanic with ALL enrolled in COG clinical trials and 681 individuals of similar backgrounds without an ALL diagnosis.

Ethnicity was assigned based on gene variations representative of European, African, and Native American ancestry. Hispanic ethnicity was defined as having more than 10% Native American gene variations, as well as having more Native American than African gene variations.

Study Findings

The researchers confirmed previous findings that high-risk genetic variations in ARID5B, GATA3, and PIP4K2A were more common in Hispanic children and were associated with an increased chance of developing ALL. They also identified high-risk variations in ERG that were associated with a 1.56-fold increased risk of ALL in Hispanic children. The individual risk, however, remains low, Dr. Yang explained.

The risk was highest (doubled) for children with the highest percentage of Native American ancestry and lowest (13%) for children with the lowest percentage. That was surprising, Dr. Yang said, because for leukemia genes discovered earlier, the effect on ALL genetic risk is usually consistent across ancestries.

In contrast, investigators found no significant increased ALL risk in African American children with the high-risk ERG variations and just a 12% elevated risk in children of European ancestry.

“We found the high-risk ERG variants were more common in Hispanic children, but also had a stronger effect in Hispanics,” Dr. Yang said. Additional research is needed to understand the mechanism involved, including possible unidentified environmental or other factors that might play a role.

The findings also suggest ERG is an important regulator of normal blood development since either somatic mutations or germline variations that disrupt gene function have now been implicated in launching leukemia. The Hispanic patients with ALL in this study rarely had both ERG germline and somatic variations at the same time. The variations themselves also did not overlap.

Disclosure: The research was funded in part by St. Baldrick’s International Scholar awards; the Robert J. Arceci award; the National Institutes of Health; and ALSAC, the fundraising and awareness organization of St. Jude. The study authors' full disclosures can be found at bloodjournal.org.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement